As AI per­me­ates clin­i­cal an­a­lyt­ics, Per­cep­tive Ad­vi­sors bets $40M in­to a sto­ried play­er in the field

When it comes to us­ing ar­ti­fi­cial in­tel­li­gence to speed up drug dis­cov­ery and de­vel­op­ment, the for­mer may be grab­bing the most at­ten­tion with the crop of AI up­starts vow­ing to find bet­ter can­di­dates faster and cheap­er, but the pos­si­bil­i­ty of ac­cel­er­at­ing ex­ist­ing clin­i­cal pro­grams is equal­ly en­tic­ing — if less vis­i­ble — to the bio­phar­ma in­dus­try.

That’s at least part of the ra­tio­nale be­hind Per­cep­tive Ad­vi­sors’ $40 mil­lion in­fu­sion in­to Saa­ma, a soft­ware com­pa­ny sell­ing a clin­i­cal da­ta an­a­lyt­ics plat­form pow­ered by AI.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.